Introduction
============

Pathogenic mutations in *BRCA1*and *BRCA2*account for the majority of but not all multiple-case breast cancer families that include members with ovarian cancer or male breast cancer. Among families with four or more female cases of breast cancer, almost 70% may be due to other predisposition genes \[[@B1]\]. Because there is a plethora of plausible breast cancer susceptibility candidates, any approach to their identification must be focused. Tumour suppressor genes that are known to be somatically inactivated in breast cancers are particularly attractive candidates and warrant close scrutiny. One such gene is *EP300*, which is a member of the histone acetyltransferase group of proteins. Its encoded protein, EP300, has been shown to regulate transcription through chromatin remodelling and by acting as a transcriptional coactivator \[[@B2]\]. It has been speculated that EP300 may play a central role in regulating responses to signals that induce growth or differentiation \[[@B3]\].

Several lines of evidence suggest that EP300 may function as a tumour suppressor. EP300 is a target for adenoviral E1A oncoprotein, the binding of which has been reported to be associated with malignant transformation. The gene is located on chromosome 22q, which is a region that exhibits frequent loss of heterozygosity in a variety of cancer types, including breast, ovarian, colorectal, gastric and pancreatic cancers \[[@B4]-[@B11]\]. Muraoka and coworkers \[[@B12]\] reported somatic mis-sense alterations in *EP300*in one of 27 colorectal cancers and in one of two gastric cancers. Subsequently, Gayther and coworkers \[[@B13]\] identified six truncating mutations in a study of 193 ovarian, breast, colorectal, pancreatic, lung and brain tumours. Two of these mutations were detected in primary breast and colorectal cancers, and four were detected in breast, colorectal and pancreatic cancer cell lines. More recently, we identified inactivating mutations in *EP300*in approximately 25% of colorectal cancer cell lines \[[@B14]\]. In addition to epithelial malignancies, EP300 has been implicated in the development of acute myeloid leukaemia, in which where translocations involving fusion of EP300 with the monocytic leukaemia zinc finger protein have occasionally been observed \[[@B15]-[@B17]\]. These data, coupled with the known involvement of EP300 in a wide range of cellular processes that are associated with malignancy, strongly suggest that it may be a tumour suppressor.

It is not known whether germline alterations in *EP300*are involved in any cancer predisposition syndrome and, with so few somatic alterations reported, it would be difficult to predict the clinical features of such a syndrome. Nevertheless, we postulated that, in addition to breast cancer, germline mutations in *EP300*may predispose to colorectal cancer because somatic mutations have previously been described in primary colorectal cancers \[[@B12],[@B13]\] and truncating mutations were identified in four of 17 cancer cell lines \[[@B14]\]. In addition, pancreatic and gastric cancers may also be a feature of such families because mutations have been described in pancreatic cell lines \[[@B13]\] and somatic missense alterations have been observed in one out of two primary gastric tumours studied \[[@B12]\].

*EP300*is a large gene spanning approximately 90 kilobases on chromosome 22q13.2; it encodes a 2414 amino acid protein with a molecular weight of approximately 260 kDa. The 8.6 kilobase mRNA transcript is encoded in 31 exons, with 5\' and 3\' noncoding regions of 778 base pairs and 1117 base pairs, respectively. Analysis of cancer cell lines suggests that inactivation of *EP300*occurs predominantly as a result of protein truncating mutations (frame shift and single nucleotide insertions/deletions) \[[@B14]\]. In order to investigate the role played by germline mutations in *EP300*in breast cancer predisposition, we undertook a mutation analysis of all 31 coding exons of *EP300*among 23 multiple-case breast cancer families, which included cases of pancreatic, gastric and/or colorectal cancer.

Methods
=======

Multiple-case breast cancer families
------------------------------------

Multiple-case breast cancer families with at least one case of pancreatic, gastric and/or colorectal cancer were ascertained through the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab; <http://www.kconfab.org/>). Confirmation of cancer diagnosis was obtained from pathology reports or medical records, and was available for 61% of breast cancer cases and for at least one case of pancreatic, gastric and/or colorectal cancer. Twenty-three multiple-case families were identified, which included at least one case of pancreatic cancer (three families), gastric cancer (nine families) and/or colorectal cancer (17 families; Table [1](#T1){ref-type="table"}).

The kConFab entrance criteria for families without a known mutation in *BRCA1*or *BRCA2*are four or more cases of breast or ovarian cancer in the same or adjacent generations (or two or more if one has \'high risk\' features, such as breast cancer diagnosis at age under 40 years, male breast cancer, bilateral breast cancer, or ovarian and breast cancer in the same woman). All of the families were tested by diagnostic laboratories for mutations in *BRCA1*and *BRCA2*by a variety of means, including single-stranded conformational polymorphism/heteroduplex analysis, protein truncation tests, chemical mismatch cleavage and/or allele specific oligonucleotide hybridization. The overall sensitivity of these tests for detecting mutations in *BRCA1*and *BRCA2*is estimated at 80%. In addition, nine out of 23 index cases were found to be mutation negative after full sequencing of *BRCA1*and/or *BRCA2*.

The index case, defined as the youngest available breast cancer patient, was identified from each of these families for mutation analysis (Table [1](#T1){ref-type="table"}). In some families, such as those of proband 0017 and 1018, there was no younger case with breast, colorectal, gastric or pancreatic cancer available for testing.

Breast cancer cases and controls
--------------------------------

The frequency of any germline variants was assessed in a series of breast cancer cases and control individuals. The 352 breast cancer patients were recruited in a hospital-based case--control study of breast cancer predisposing genes, carried out at breast clinics in the Wessex region of southern England. They were selected on the basis of age at onset under 40 years (203 cases), a family history of breast cancer (defined as two or more cases of breast cancer in a first-degree or second-degree female relative) irrespective of age at onset (105 cases), or bilateral breast cancer diagnosed after 39 years of age irrespective of family history (44 cases). All breast cancer patients were systematically identified through breast clinics in the Wessex region of southern England, as described previously \[[@B18],[@B19]\]. The age range of the breast cancer patients was 19--79 years, with a mean age of 38 years. The control individuals were representative of the population from which the patients arose, and included 254 Caucasian female volunteers who either were staff at the Princess Anne Hospital, Southampton, UK or were patients attending for non-neoplastic disease conditions. The age range of the control individuals was 18--84 years, with a mean age of 39 years. For all groups normal genomic DNA was prepared from blood lymphocytes. Comparisons of genotype frequencies were analyzed using Fisher\'s exact test using the relevant 2 × 2 contingency tables. All statistical calculations were two-sided and performed using InStat version 3.01 (GraphPad Software Inc., San Diego, CA, USA). *P*\< 0.05 was considered statistically significant.

Mutation analysis
-----------------

Normal genomic DNA was prepared from blood lymphocytes for all index cases and control individuals. All 31 coding exons of *EP300*, including splice junctions, were amplified from genomic DNA using primers binding to complementary intronic regions (Table [2](#T2){ref-type="table"}). Because of their larger size, exons 2, 14 and 31 were amplified in overlapping segments using primers complementary to exonic sequences.

PCR was performed in a reaction volume of 20 μl containing 50 ng genomic DNA, 25 ng of each primer, 10× reaction buffer, 1 μl of a nucleotide mix (4 mmol/l each of dCTP, dTTP, dGTP and dATP) and 0.5 μ Taq DNA polymerase (AmplitaqGold; Perkin-Elmer, Branchbury, NJ, USA). The standard program used for PCR amplification was as follows: one initial denaturation step of 94°C for 5 min, 35 cycles of 30 s denaturation at 94°C, 30 s of annealing (50--60°C), and 60 s extension at 72°C, followed by a final elongation cycle at 72°C for 5 min. All PCR products were checked for purity on 2% agarose gels. Before denaturing HPLC (DHPLC) analysis, the PCR products were denatured at 95°C for 5 min and gradually cooled to 65°C at a rate of 1°C/min. The optimal melting temperatures for each PCR fragment are shown in Table [2](#T2){ref-type="table"} and were calculated using the DHPLC Melt program <http://insertion.stanford.edu/melt.html>.

Samples of 4 μl were then analyzed on a Varian-Helix DHPLC system (Varian, Inc., Palo Alto, CA, USA) using a Helix DNA 75 mm × 3.0 mm column. Analysis was carried out at the recommended melt temperature using the universal elution conditions recommended by the manufacturer. Briefly, DNA was eluted at a flow rate of 0.45 ml/min with a total running time of 8 min and 50 s in a linear acetonitrile gradient made by mixing buffer A (0.1 mmol/l triethylammonium acetate, 0.1 mmol/l EDTA) with buffer B (0.1 mol/l triethylammonium acetate, 25% acetonitrile, 0.1 nmol/l EDTA). Initially, the samples were eluted for 30 s with a constant buffer B content of 45%. This was followed by a 5 min 30 s period during which the buffer B concentration increased from 45% to 68%. The buffer B concentration was then held at 68% for 1 min and thereafter decreased to 45% for a further 1 min and 50 s. Samples with variations in elution profiles were identified using the Varian Star Reviewer software package.

For each variant elution profile, the genomic DNA was re-amplified with the DHPLC primers and sequenced using the Big-Dye sequencing chemistry (Perkin-Elmer).

Results
=======

DHPLC analysis of the youngest available member affected with breast cancer from each of the families identified only two with variations in elution profiles, both of which were in exon 2b of *EP300*(Fig. [1](#F1){ref-type="fig"}). Individual 0017 had breast cancer (age at onset 70 years) and a family history of female breast cancer (three cases) and gastric cancer (one case; age at onset 45 years). Individual 0318 had breast and ovarian cancer (age at onset 41 and 46 years, respectively) and a family history of biliary tract cancer (age at onset 80 years), breast cancer (seven cases), ovarian cancer (two cases), bowel cancer (age at onset 73 years) and gastric cancer (age at onset 70 years; Table [1](#T1){ref-type="table"}). Sequencing revealed that both individuals harboured a heterozygous G1830A substitution (NM_001429; gi:4557556) in codon 211, resulting in a glycine to serine substitution.

To further investigate the possible role of this variant in cancer predisposition, we conducted a case--control study using a UK-based series of 352 breast cancer patients and 254 control individuals. The frequency of heterozygous carriers of the Ser211 variant was determined by DHPLC analysis. We did not find any significant difference in the frequency of carriers of the Ser211 variant between the patients (14/352 \[4.0%\]) and control individuals (7/254 \[2.8%\]; *P*= 0.5).

Discussion
==========

The *EP300*gene is located at the centre of a region of frequent loss of heterozygosity in breast and ovarian cancer, and has recently been implicated as a tumour suppressor gene by the identification of somatic alterations in breast, colon, pancreatic and gastric primary tumours and cell lines. As such, we reasoned that *EP300*was a plausible susceptibility gene in multiple-case breast and ovarian cancer families with additional cases of gastric, pancreatic and/or colorectal cancer. However, in the present study we identified only one coding variant of *EP300*in two out of 23 such multiple-case cancer families. This glycine to serine substitution is unlikely to have any detrimental impact on the activity of *EP300*because both are small, neutral and uncharged amino acids, and the substitution is located in a region of the EP300 protein with no recognized functional domain. The polymorphism has no effect on exonic splicing enhancers as predicted by the ESEfinder program <http://exon.cshl.org/cgi-bin/ESE>. Furthermore, the fact that no significant difference was detected in the frequency of this variant among 254 control individuals and 352 breast cancer cases further suggests that it represents a nonpathogenic polymorphism. Given that DHPLC is a robust and sensitive screening technique, we consider it unlikely that we missed any pathogenic variants among the 23 index cases analyzed. In particular, we analyzed each PCR fragment at all the temperatures recommended by the DHPLC Melt algorithm, and under these conditions DHPLC has been reported to have a sensitivity of 99.4% \[[@B20]\].

In the present study we restricted our analysis to non-*BRCA1*/*BRCA2*mutation families with a family history that included gastric, pancreatic and/or colorectal cancer because somatic mutations have been identified in *EP300*in these cancer types. However, it is possible that this may not be a reliable indicator of a familial cancer phenotype generated by germline mutations in *EP300*, given that our selection criteria were based on identification of mutations in only a small number of cancers \[[@B12],[@B13]\]. Furthermore, we tested only *2*3 probands and can only conclude that germline *EP300*mutations are not common in this sample set.

Conclusion
==========

Based on the spectrum of mutations observed in sporadic tumors, we hypothesized that germline mutations in *EP300*may account for some breast cancer families that contain cases of gastric, pancreatic and/or colorectal cancer. Analysis of 23 probands suggests that germline *EP300*mutations do not play a major role in breast cancer families with a history of these other cancer types. However, the study does not entirely exclude the possibility that *EP300*may represent a breast cancer susceptibility gene, and more extensive studies of non-*BRCA1/BRCA2*breast cancer families, irrespective of a history of other cancer types, are warranted.
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Figures and Tables
==================

![Denaturing HPLC (DHPLC) elution profile of *EP300*exon 2b run at 60°C. Individuals 0318 (red trace) and 0017 (green trace) exhibit two distinct peaks compared with control individual 1115 (blue track) with only one major peak.](bcr803-1){#F1}

###### 

Features of the probands and their families analyzed for *EP300*germline mutations

                                 Number of tumours in the family^1^                   
  ------ ------------ ---------- ------------------------------------ --- --- --- --- ---
  0011   br           32         8                                    0   1   0   2   0
  0017   br           70         3                                    0   0   0   1   0
  0187   br/bil       28/39      7                                    0   1   0   0   0
  0318   br/ov        41/46      7                                    2   1   0   1   1
  0329   br           43         3                                    0   1   0   0   1
  0342   br           41         2                                    0   0   0   1   1
  0458   br           46         4                                    0   0   0   1   3
  0580   br           44         5                                    1   2   0   0   1
  0894   br           45         5                                    0   0   1   0   1
  0933   br           50         4                                    0   0   1   0   1
  0990   br           42         4                                    0   1   0   0   2
  1018   br           66         5                                    0   3   0   1   8
  1115   br           49         6                                    1   1   0   3   4
  1279   br           41         4                                    0   2   0   0   4
  1566   br           53         4                                    0   1   0   1   4
  1853   br/bil       43/47      2                                    0   2   0   0   1
  1890   br/stom      21/49      2                                    0   6   0   0   5
  1934   br           49         4                                    0   3   0   0   3
  2033   br/stom/th   37/58/59   3                                    0   0   0   1   1
  2220   br           29         5                                    0   1   1   0   4
  2263   br           38         4                                    0   4   0   0   1
  4734   br           49         6                                    0   2   0   0   7
  0001   br           37         2                                    0   1   0   0   0

^1^The number of tumors includes proband\'s tumors. bil, bilateral breast cancer; br, breast cancer; ov, ovarian cancer; stom, stomach cancer; th, thyroid cancer.

###### 

Primers used to amplify exons and splice junctions of *EP300*

  Exon   Forward^1^                  Reverse                       Product size (base pairs)   Predicted melt temperature (°C)^2^
  ------ --------------------------- ----------------------------- --------------------------- ------------------------------------
  1      Atttcctgaggattctggtt        cgcaccgagtagaaaagat           202                         57,62
  2a     gacctttgtcttttcccttt        accctgatttggtccacta           372                         60
  2b     aggcaggcttgacttctc          gcacacaaaccaaaactgta          372                         60
  3      ttgcttattttgttttcttttg      atgccagtttgaaaacaagt          254                         52,57
  4      agcacattatgactcctaccatt     acagtaaccctgtgggtcc           333                         57,62
  5      cattaacctgctcttgaaaaa       actggtgagactttaaaactt         210                         57
  6      ttctcaccagcattaatttgt       tgacacaaccaataccatgt          335                         5560
  7      tgtctcctgttatttcattttg      tgtaatgtgacccagggtat          161                         57
  8      aactatttggtgaccccttt        gaatgagacgtgtccacaat          193                         54,59
  9      aaatgctgacatgatattacagtgg   ccacaacaggttcaatcttgg         212                         58
  10     tgttacctggtggtagttcc        caaacagaaatataacaaaaacca      266                         58,53
  11     aatattttgtggggtttgtg        gtacaccggggattctttta          215                         58,53
  12     aatttcacaaaggcattcag        aggtaaaggccaaagagatt          196                         55,60
  13     gaagcagtttggtgatttgt        tgaaaaatccacttatgagaca        201                         55,60
  14a    tgttctgaattgctgtcttg        ccttggagggggatgtag            311                         56,61
  14b    acagtcccaggctctaca          atgattctgcctaaatccaa          231                         62,57
  15     gcgtgtgtctcacctacttcc       ggtcatatacatatcaaacagtaattg   257                         60
  16     tgagaaagggtgttcagatt        tcttcagctacctccagaac          261                         5358
  17     tggaactaatttcaaatgccc       ccaccaaatacttacagggattc       169                         54,59
  18     ggatgatactccatctcccg        tcccagaaaagttaaagtcaaatc      350                         57
  19     tgtccttaaggcctctgtgc        cactccctggacatgtggac          190                         60
  20     acagttcaccccagtatggc        tgtgcataatcactggacaaca        174                         59
  21     tcctttggttagaacagcag        tcaagagaatgaaagggaaa          196                         56
  22     attgcaagttttcatttggt        ttccagagaaagtaacaacg          171                         58
  23     cggtttatctaagttgtgtaagca    ggcttcagataagttttgcca         160                         54
  24     aacaacagtaaatttgcacctca     tttggatccacgaggagag           241                         54,59
  25     gtggttcccccaccatct          cggagctagccactgtgag           205                         60
  26     tttcctcttcatttctcttca       ccagaatgccatgctagttaaa        239                         55
  27     ttccttaatgttctttctctttg     ttccagatctattgtcagca          242                         54,59
  28     catgcatgttttcacaggat        agaagtttcaaaggaaactcaatg      213                         57
  29     tttcttgtctcctttgtgctt       agaaatcttgccgtttttc           236                         59
  30     gaggccctgtctcaaaaa          ctcctccttcccacaacc            350                         62
  31a    gagagtttacgtgcacctcct       ccattggttttccgtttg            303                         61
  31b    atcctgccagaagatgaag         gttggtgtcgttggagtg            309                         62
  31c    gtggttgggcagcaacag          ctgctctctgaatctgcatt          289                         63
  31d    ctcagccaccccttccag          ttcaaaggttgaccatgc            337                         57,62
  31     gccagccatgatgtcagt          gcatggtaggtggctgta            320                         62
  31f    gctgttggctgcattcat          gatgtctcggaattgtgaag          310                         62
  31g    ctcagcagatgaacatgaac        catctgttgctgaaggagtc          314                         61
  31h    aggcaggtgccagtctac          agctaccagtccaggatg            305                         62
  31i    ctcagccttctccacacc          gctcccaaaatactacaagg          273                         61

^1^All primer sequences are shown in the 5\' to 3\' direction. ^2^The optimal melting temperature for each PCR fragment were calculated using the DHPLC Melt program <http://insertion.stanford.edu/melt.html>. Where more than one optimal temperature was predicted, both were used in the DHPLC analysis.
